Valencell: Empowering a New Era in Remote Patient Monitoring

article image

A B2B leader in PPG technology for fitness applications, Valencell is moving into medtech with a unique sensor and algorithm technology it says has the potential to enable clinical-grade blood pressure monitoring using common mobile devices such as smartphones and smartwatches.

Interest in remote healthcare—including telehealth, self-care apps, and remote patient monitoring (RPM)—mushroomed during the COVID-19 pandemic, spurring a goldrush of investment, M&A, and product development activity in digital health. Although telehealth visits have leveled off in recent months with the gradual return to in-person care, they remain well above pre-pandemic volumes. And going forward, remote care of all sorts is likely to expand further, driven by growing patient demand for more convenient healthcare delivery options, greater acceptance and adoption of patient self-care, and ongoing advances in remote monitoring technology. These trends are expected to drive strong growth in the digital health sector for years to come.


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: